Announcements
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
- Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Key statistics
As of last trade Immutep Ltd (PRRUF:PKC) traded at 0.2641, -13.72% below its 52-week high of 0.3061, set on May 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.284 |
---|---|
High | 0.284 |
Low | 0.2641 |
Bid | -- |
Offer | -- |
Previous close | 0.2641 |
Average volume | 9.00k |
---|---|
Shares outstanding | 1.19bn |
Free float | 1.14bn |
P/E (TTM) | -- |
Market cap | 499.31m AUD |
EPS (TTM) | -0.0394 AUD |
Data delayed at least 15 minutes, as of Apr 25 2024 16:41 BST.
More ▼